异位表达
小RNA
生物
癌症研究
淋巴瘤
调节器
原癌基因蛋白质c-myc
细胞生长
B细胞
基因表达调控
遗传学
细胞培养
基因
免疫学
抗体
作者
Dawoom Jeong,Jinwoo Kim,Jehyun Nam,Hokeun Sun,Yong‐ho Lee,T.-J. Lee,Ricardo C.T. Aguiar,S-W Kim
出处
期刊:Leukemia
[Springer Nature]
日期:2015-04-27
卷期号:29 (9): 1868-1874
被引量:57
摘要
The contribution of microRNAs to lymphoma biology is not fully understood. In particular, it remains untested whether microRNA dysregulation could contribute to the emergence of the aggressive subset of B-cell lymphomas that coexpress MYC and BCL2. Here, we identify microRNA-124 (miR-124) as a negative regulator of MYC and BCL2 expression in B-cell lymphomas. Concordantly, stable or transient ectopic expression of miR-124 suppressed cell proliferation and survival, whereas genetic inhibition of this miRNA enhanced the fitness of these tumors. Mechanistically, the activities of miR-124 towards MYC and BCL2 intersect with both oncogenic and tumor-suppressive pathways. In respect to the former, we show that miR-124 directly targets nuclear factor-κB (NF-κB) p65, and using genetic approaches, we demonstrate that this interaction accounts for the miR-124-mediated suppression of MYC and BCL2. We also characterized miR-124 promoter region and identified a functional p53 binding site. In agreement with this finding, endogenous or ectopic expression of wild-type, but not mutant, p53 increased miR-124 levels and suppressed p65, MYC and BCL2. Our data unveil an miRNA-dependent regulatory circuitry that links p53 to the NF-κB pathway, which when disrupted in B-cell lymphoma may be associated with aberrant coexpression of MYC and BCL2 and poor prognosis.
科研通智能强力驱动
Strongly Powered by AbleSci AI